Anti-SARS CoV-2 IgG in COVID-19 Patients with Hematological Diseases: A Single-center, Retrospective Study in Japan

혈액 질환이 있는 COVID-19 환자의 Anti-SARS CoV-2 IgG: 일본의 단일 센터, 후향적 연구

Published on
Journal: Internal medicine (Tokyo, Japan)
[키워드]
[저자] Takayuki Fujii, Masao Hagihara, Keiko Mitamura, Shiori Nakashima, Shin Ohara, Tomoyuki Uchida, Morihiro Inoue, Moe Okuda, Atsuhiro Yasuhara, Jurika Murakami, Calvin Duong, Kiyoko Iwatsuki-Horimoto, Seiya Yamayoshi, Yoshihiro Kawaoka
[Category] COVID19(2023년), MERS, SARS, 진단, 치료기술,
PMC URL    [DOI] 10.2169/internalmedicine.9209-21    
[Article Type] Article
[Source] PMC

Abstract
Objective Coronavirus disease (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has spread globally. Although the relationship between anti-SARS-CoV-2 immunoglobulin G (IgG) antibodies and COVID-19 severity has been reported, information is lacking regarding the seropositivity of patients with particular types of diseases, including hematological diseases. Methods In this single-center, retrospective study, we compared SARS-CoV-2 IgG positivity between patients with hematological diseases and those with non-hematological diseases. Results In total, 77 adult COVID-19 patients were enrolled. Of these, 30 had hematological disorders, and 47 had non-hematological disorders. The IgG antibody against the receptor-binding domain of the spike protein was detected less frequently in patients with hematological diseases (60.0%) than in those with non-hematological diseases (91.5%; p=0.029). Rituximab use was significantly associated with seronegativity (p=0.010). Conclusion Patients with hematological diseases are less likely to develop anti-SARS-CoV-2 antibodies than those with non-hematological diseases, which may explain the poor outcomes of COVID-19 patients in this high-risk group.
Keywords: COVID-19; SARS-CoV-2; SARS-CoV-2 IgG antibodies.

All Keywords
【저자키워드】 COVID-19, SARS-CoV-2, SARS-CoV-2 IgG antibodies, 【초록키워드】 coronavirus disease, IgG, coronavirus, Diseases, antibody, COVID-19 severity, outcome, severe acute respiratory syndrome Coronavirus, anti-SARS-CoV-2, rituximab, Spike protein, Spread, Retrospective study, anti-SARS-CoV-2 antibodies, Immunoglobulin G, IgG antibody, Receptor-binding domain, Immunoglobulin, anti-SARS-CoV-2 antibody, IgG antibodies, Patient, Seropositivity, respiratory, information, disease, SARS-CoV-2 IgG, COVID-19 patients, COVID-19 patient, Seronegativity, acute respiratory syndrome, acute respiratory syndrome coronavirus, acute respiratory syndrome coronavirus 2, disorders, SARS-CoV-2 IgG antibodies, single-center, hematological, objective, Result, enrolled, develop, caused, significantly, reported, less, the spike protein, the receptor-binding domain, explain, adult COVID-19 patient, 【제목키워드】 IgG, Japan,
{{{ 추상적인 }}} 객관적인 코로나바이러스 감염증(COVID-19)은 중증급성호흡기증후군 코로나바이러스 2(SARS-CoV-2)로 인해 전 세계적으로 확산되었습니다. 항SARS-CoV-2 면역글로불린 G(IgG) 항체와 COVID-19 중증도 사이의 관계가 보고되었지만 혈액 질환을 포함한 특정 유형의 질병을 가진 환자의 혈청 양성에 대한 정보는 부족합니다. 방법 이 단일 센터 후향적 연구에서 우리는 혈액 질환 환자와 비혈액 질환 환자 간의 SARS-CoV-2 IgG 양성을 비교했습니다. 결과 총 77명의 성인 COVID-19 환자가 등록되었습니다. 이 중 30명은 혈액질환, 47명은 비혈액질환이었다. 스파이크 단백질의 수용체 결합 도메인에 대한 IgG 항체는 혈액 질환이 있는 환자(60.0%)에서 비혈액 질환이 있는 환자(91.5%; p=0.029)보다 덜 빈번하게 검출되었다. 리툭시맙 사용은 혈청음성도와 유의한 관련이 있었습니다(p=0.010). 결론 혈액 질환이 있는 환자는 비-혈액 질환이 있는 환자보다 항 SARS-CoV-2 항체가 발생할 가능성이 적기 때문에 이 고위험군에서 COVID-19 환자의 좋지 않은 결과를 설명할 수 있습니다. {{ 키워드: }} 코로나19; 사스 코로나바이러스 2; SARS-CoV-2 IgG 항체.